Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18854284rdf:typepubmed:Citationlld:pubmed
pubmed-article:18854284lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0026764lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0039736lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0006560lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:18854284lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:18854284pubmed:issue5lld:pubmed
pubmed-article:18854284pubmed:dateCreated2008-10-15lld:pubmed
pubmed-article:18854284pubmed:abstractTextFew studies have focused on factors affecting outcome in patients with multiple myeloma (MM) treated with thalidomide-based therapy. We investigated factors affecting response, progression-free survival (PFS), and overall survival (OS) in patients with MM treated with the thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) regimen with the aim to select patients benefiting more from this therapy.lld:pubmed
pubmed-article:18854284pubmed:languageenglld:pubmed
pubmed-article:18854284pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18854284pubmed:citationSubsetIMlld:pubmed
pubmed-article:18854284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18854284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18854284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18854284pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18854284pubmed:statusMEDLINElld:pubmed
pubmed-article:18854284pubmed:monthOctlld:pubmed
pubmed-article:18854284pubmed:issn1557-9190lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:VisaniGiusepp...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:LeoniPietroPlld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:GalieniPieroPlld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:CandelaMarcoMlld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:OffidaniMassi...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:CorvattaLaura...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:BurattiniMaur...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:GiuliodoriLuc...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:BrunoriMarino...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:CenturioniRic...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:MeleAnnaAlld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:MarconiMonica...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:CatariniMassi...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:AlesianiFranc...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:PiersantelliM...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:FerrantiMario...lld:pubmed
pubmed-article:18854284pubmed:authorpubmed-author:PolloniClaudi...lld:pubmed
pubmed-article:18854284pubmed:issnTypePrintlld:pubmed
pubmed-article:18854284pubmed:volume8lld:pubmed
pubmed-article:18854284pubmed:ownerNLMlld:pubmed
pubmed-article:18854284pubmed:authorsCompleteYlld:pubmed
pubmed-article:18854284pubmed:pagination294-9lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:meshHeadingpubmed-meshheading:18854284...lld:pubmed
pubmed-article:18854284pubmed:year2008lld:pubmed
pubmed-article:18854284pubmed:articleTitleSerum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.lld:pubmed
pubmed-article:18854284pubmed:affiliationClinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti Ancona, Italy. m.offidani@ospedaliriuniti.marche.itlld:pubmed
pubmed-article:18854284pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:6927entrezgene:pubmedpubmed-article:18854284lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18854284lld:entrezgene
lhgdn:association:7745lhgdn:found_inpubmed-article:18854284lld:lhgdn